Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina

This study has been terminated.
(Business Decision (please see below))
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01549977
First received: March 6, 2012
Last updated: October 30, 2013
Last verified: October 2013
  Purpose

The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo as an add on to stable anti-anginal therapy, on the total exercise time of participants with Chronic Stable Angina.


Condition Intervention Phase
Angina
Drug: Febuxostat
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Exercise Tolerance in Subjects With Chronic Stable Angina

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change From Baseline in Exercise Treadmill Testing (ETT) Duration at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    The change between the duration of ETT at Week 12 relative to Baseline. ETTs were conducted using the modified Bruce Protocol. Participants exercised on a treadmill, starting at 1.7 mph and 0% incline. The intensity of exercise (speed and/or incline) was increased at 3 minute intervals.


Secondary Outcome Measures:
  • Change From Baseline in Time to Onset of Angina During ETT at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    The change between the time to onset of angina during the exercise treadmill test (ETT) at Week 12 relative to Baseline.

  • Change From Baseline in Time to Onset of ≥1 mm ST-segment Depression During ETT at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    The change between the time to onset of ≥1 mm ST-segment depression during exercise treadmill test (ETT) at Week 12 relative to Baseline. ST-segment is measured by electrocardiography (ECG) and represents the interval between ventricular depolarization and repolarization.

  • Change From Baseline in Maximum ST-segment Depression During ETT at Week 12 [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    The change between the maximum ST-segment depression during ETT at Week 12 relative to Baseline. ST-segment is measured by electrocardiography (ECG) and represents the interval between ventricular depolarization and repolarization.

  • Percentage of Participants Stopping ETT Due to Angina at Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    The percentage of participants who had to stop exercise treatment testing (ETT) due to experiencing angina symptoms at Week 12.


Enrollment: 1
Study Start Date: July 2012
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Febuxostat 80 mg
Febuxostat 80 mg, tablets, orally, once daily for up to 12 weeks.
Drug: Febuxostat
Febuxostat tablets
Other Names:
  • TMX-67
  • Uloric
Placebo Comparator: Placebo
Febuxostat placebo-matching tablets, orally, once daily for up to 12 weeks.
Drug: Placebo
Febuxostat placebo-matching tablets

Detailed Description:

This is a phase 2 multicenter, randomized, placebo-controlled double-blind study. This study is comprised of a single-blind placebo run-in qualifying phase lasting approximately 3 weeks and a double-blind treatment phase lasting 12 weeks. A safety follow-up visit is scheduled for 2 weeks after last dose of study drug.

All participants will undergo 3 visits during a 3 week, run-in phase (Days -21 to Day 1). During the run-in phase, all participants will receive single-blind placebo. Two exercise treadmill tests (ETTs) will be conducted using the modified Bruce Protocol at Day -14 and at Day -7. The results from the Day -7 ETT will be considered as Baseline.

A total of approximately 100 participants will be randomized 1:1 to receive either febuxostat 80 mg once daily (QD) or placebo QD in a double-blind treatment for 12 weeks, and 5 more visits.

All participants will complete the Seattle Angina Questionnaire (SAQ) and Euroqol 5 dimension (EQ-5D) quality-of-life measurements at Day 1, Week 6 and Week 12/Early Termination (ET) Visit. The investigator will also rate the overall severity of the participant's angina at each visit based on the Canadian Cardiovascular Society Grading of Angina (CCSGA).

This 12-week phase 2 proof-of-concept study was designed to assess the effect of febuxostat as an add-on to stable anti-anginal therapy on the total exercise time of participants with chronic stable angina and a serum urate ≥5 mg/dL. At this time, Takeda has decided to terminate the study for business reasons.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative, signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. The participant has an serum urate (sUA) ≥5.0 mg/dL.
  4. The participant has a history of angina, defined as:

    1. Minimum of 3-month history of stable angina (at least 2 episodes of chest pain or anginal equivalent in the past 30 days); AND
    2. Receiving at least one chronic anti-ischemic medication(s), including beta blockers, calcium channel blockers and long acting nitrates (doses must be stable for at least 30 days prior to Screening [Day -21]); AND
    3. Coronary artery disease, as defined by:

      • ≥50 % stenosis of ≥1 major coronary artery confirmed by angiography; OR
      • Documented prior myocardial infarction (MI) by enzymes/electrocardiogram (ECG) changes; OR
      • Documented myocardial imaging stress test; OR
      • Prior history of coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) greater than 3 months prior to Screening Day -21.
  5. The participant has estimated glomerular filtration rate (eGFR) >30 mL/min by Modification of Diet in Renal Disease (MDRD) at the Screening visit Day -21.
  6. The participant has a normal/controlled blood pressure at Day 1/Randomization, as defined by the mean of three sitting blood pressures not exceeding 140/90.
  7. The participant is male or female and aged 18 to 85 years, inclusive.
  8. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.
  9. Participant is on stable (30 days) medication doses prescribed for any underlying medical condition (ie; hypertension, angina) and will remain on stable doses throughout the study duration.
  10. Participant is able to take, in an ongoing manner, nitroglycerine for anginal symptoms.
  11. Symptom-limited exercise duration, during ETT at Day -14 and Day -7, on the modified Bruce Protocol.
  12. Exercise duration for the two ETTs at Day -14 and Day -7 did not differ by more than 20% of the longer of the two times, and did not differ by more than 60 seconds. To be confirmed by the Core ECG Lab prior to the subject being randomized.
  13. Definite ECG signs of ischemia during the ETT at both Day -14 and Day -7 (i.e., 1 additional mm of horizontal or down-sloping ST-segment depression beyond baseline and ≥1 mm below the isoelectric line) are present in at least one standard ECG lead during ETT. The Day -7 ≥1 mm ST-segment depression must be verified by the Core ECG Lab prior to participant being randomized.

Exclusion Criteria:

  1. The participant has received any investigational compound within 30 days prior to Screening Day -21.
  2. The participant has received allopurinol or febuxostat in a previous clinical study or as a therapeutic agent.
  3. The participant has gout or secondary hyperuricemia (e.g., due to myeloproliferative disorder, or organ transplant) or has experienced a gout flare.
  4. The participant has a history of xanthinuria.
  5. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  6. The participant has a history of hypersensitivity or allergies to febuxostat or nitroglycerine.
  7. The participant has hemoglobin <10 g/L at Screening Day -21.
  8. The participant has a systolic blood pressure of less than 100 mmHg.
  9. The participant has a blood pressure of greater than 200/100 at any Screening or Run-in visit.
  10. The participant has a history or clinical manifestations of a significant medical condition that might affect his/her ability to complete the study.
  11. The participant has any of the following at any Screening or Run-in visit:

    1. Resting ST-segment depression ≥1 mm in any lead.
    2. Left bundle-branch block.
    3. New York Heart Association Class III or IV heart failure.
    4. Acute coronary syndrome or a coronary revascularization procedure within 3 months of Screening.
    5. Wolff-Parkinson-White syndrome.
    6. Pacemaker or implantable cardioverter defibrillator.
    7. Arrhythmias (i.e., SVT, atrial fibrillation/flutter, VT, or rate related bundle branch blocks).
    8. Left ventricular hypertrophy with repolarization abnormalities.
  12. The participant has a recent history (within the last 3 months) of myocardial infarction, heart failure, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack.
  13. The participant has a contraindication for using nitrates (severe anemia, increased intracranial pressure, and those with a known sensitivity or hypersensitivity to nitroglycerin or its ingredients, or other nitrates or nitrites; concomitant use either regularly and/or intermittently, with phosphodiesterase type 5 (PDE5) inhibitors).
  14. The participant has unstable angina that:

    1. Occurs when the participant is at rest.
    2. Is prolonged, usually greater than 20 minutes.
    3. Occurs with increasing in intensity, duration, and/or frequency.
    4. Responds poorly to nitroglycerin (i.e., does not go away after three doses of nitroglycerin or returns after the nitroglycerin helped at first).
  15. The participant is unable to exercise sufficiently to complete ETT due to leg claudication, arthritis, deconditioning, or associated pulmonary disease.
  16. The participant has severe or critical valvular disease documented by echocardiogram, or congenital heart disease.
  17. The participant has left ventricular ejection fraction (LVEF) less than 35%, as documented by echocardiogram or angiography.
  18. The participant has clinically significant cardiac conduction defects (i.e., second- or third-degree atrioventricular block, sick sinus syndrome or a QTc >500 msec) at Day -21.
  19. The participant has active acute myocarditis/pericarditis within the 3 months prior to Screening Day -21.
  20. The participant has hypertrophic cardiomyopathy.
  21. The participant has an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level of greater than 2.0 times the upper limit of normal, has active liver disease, or jaundice.
  22. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 5 years prior to the Screening Visit.
  23. The participant is required or expected to require excluded medications digoxin and digoxin-containing compounds.
  24. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  25. The participant has participated in another clinical study within the past 30 days.
  26. The participant has a history of extracorporeal external counterpulsation treatment for chronic stable angina within 3 months prior to screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01549977

Locations
United States, California
Carmichael, California, United States
Fresno, California, United States
Irvine, California, United States
Paramount, California, United States
Sacramento, California, United States
San Diego, California, United States
United States, Florida
Tampa, Florida, United States
United States, Georgia
Dunwoody, Georgia, United States
Suwanee, Georgia, United States
United States, Kentucky
Lexington, Kentucky, United States
United States, Missouri
St. Louis, Missouri, United States
St. Peters, Missouri, United States
United States, North Carolina
Salisbury, North Carolina, United States
United States, Ohio
Columbus, Ohio, United States
Lyndhurst, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Tipton, Pennsylvania, United States
United States, Texas
San Antonio, Texas, United States
United States, Virginia
Manassas, Virginia, United States
United States, Washington
Port Orchard, Washington, United States
United States, Wisconsin
Madison, Wisconsin, United States
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director Clinical Science Takeda
  More Information

Additional Information:
No publications provided

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT01549977     History of Changes
Other Study ID Numbers: TMX-67_207, U1111-1125-1278
Study First Received: March 6, 2012
Results First Received: October 30, 2013
Last Updated: October 30, 2013
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Takeda:
Drug Therapy

Additional relevant MeSH terms:
Angina Pectoris
Angina, Stable
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Chest Pain
Pain
Signs and Symptoms
Febuxostat
Gout Suppressants
Antirheumatic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2014